# Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia

Study · id `cardio:ct-nct01420549` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01420549](<https://clinicaltrials.gov/study/NCT01420549>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01420549

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 129 participants.

## Technical summary

Registry record NCT01420549. Randomized; no masking; primary purpose treatment. Start 2013-03 (registry gives no type); primary completion 2014-11 (actual). Results posted on 2020-01-22.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 129 participants (enrolled count; ClinicalTrials.gov record NCT01420549, source copy `cardio:ctgov-nct01420549-2020-01-22`, retrieved 2026-10-31)
- Start date: 2013-03 (registry gives no type) (ClinicalTrials.gov record NCT01420549, source copy `cardio:ctgov-nct01420549-2020-01-22`, retrieved 2026-10-31)
- Primary completion: 2014-11 (actual) (ClinicalTrials.gov record NCT01420549, source copy `cardio:ctgov-nct01420549-2020-01-22`, retrieved 2026-10-31)
- Completion: 2014-11 (actual) (ClinicalTrials.gov record NCT01420549, source copy `cardio:ctgov-nct01420549-2020-01-22`, retrieved 2026-10-31)
- Results first posted: 2020-01-22 (ClinicalTrials.gov record NCT01420549, source copy `cardio:ctgov-nct01420549-2020-01-22`, retrieved 2026-10-31)
- Countries: Brazil (ClinicalTrials.gov record NCT01420549, source copy `cardio:ctgov-nct01420549-2020-01-22`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01420549-2020-01-22`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia
- Acronym: LANCE
- Condition: Hypercholesterolemia
- Condition: Dyslipidemia
- Intervention (Drug): Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according to clinical evaluation.
- Intervention (Drug): Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according to clinical evaluation.
- Lead sponsor: Ache Laboratorios Farmaceuticos S.A.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)

## Provenance

Content hash: 8605b50b57323b007d1edbb2f3827987d6be75c1641a32f2892ee5b6ad057d20
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
